NCT00182455

Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)

Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial.

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: McMaster University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

SSRI's are considered first-line treatments for GSP, however many patients continue to have significant symptoms despite an adequate trial of an SSRI. Topiramate, a drug, which targets the glutamate system in the brain, has been shown to improve symptoms of social phobia when used on its own and has also been used as an additive treatment in other anxiety disorders. This study will test the efficacy of adding topiramate to a subject's current SSRI in cases of GSP which are considered to be treatment-resistant.

Conditions

• Social Phobia

Interventions

Type	Name	Description
DRUG	Topiramate	25 - 400 mg/day x 12 weeks
DRUG	Placebo	25 - 400 mg/day x 12 weeks

Timeline

• Start date: 2004-03-01
• Primary completion: 2018-12-01
• Completion: 2018-12-01
• First posted: 2005-09-16
• Last updated: 2020-09-02

Locations

1 site across 1 country: Canada